Patients with neuroendocrine tumours who may have a much longer life expectancy than those with aggressive tumours report placing a higher priority on QoL factors, such as remaining independent, compared with longer survival as a primary treatment goal. However, they often feel that their clinicians do not share their priorities, shows...